NKTX
Nkarta, Inc.
Healthcare — Biotechnology
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Price History
Fundamentals
| Market Cap | $203.90M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.73 |
| EPS (TTM) | $-1.35 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -30.07% |
| Debt/Equity | 26.24 |
| Recommendation | Strong Buy 1.1 |
| Analyst Target | $11.33 |
| Analysts | 6 |
| Next Earnings | May 12, 2026 |
| Indexes | - |
Technical Indicators
| RSI (14) | 62.6 |
| Beta | 0.90 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.65 |
| 52-Week Low | $1.68 |
| 50-Day Avg | $2.89 |
| 200-Day Avg | $2.33 |
| Avg Volume | 719.4K |
| Volume | 732.1K |
Performance Analysis
BULLISHNKTX shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:22 UTC
Back to Screener Export Report